Immunomodulatory therapy with anti-interleukin-1 after photorefractive keratectomy in the New Zealand white rabbit

Kenneth R. Taylor, Vasudha A. Panday, Matthew C. Caldwell, W. Matthew Petroll, Douglas A. Apsey, Charles D. Reilly

Research output: Contribution to journalArticle

Abstract

Purpose To examine the safety and efficacy of topical anti-interleukin-1 (anti-IL-1) following photorefractive keratectomy (PRK) in rabbit eyes. Setting Joint Warfighter Refractive Surgery Center, Lackland Air Force Base, Texas, USA. Design Experimental study. Methods After standard PRK, 48 eyes of 24 New Zealand white rabbits were divided into 4 treatment arms and 1 control arm. Eyes in the treatment arms were randomized to receive fluorometholone 0.1% or an anti-IL-1 suspension (2.50 mg, 1.25 mg, or 0.25 mg doses) plus standard moxifloxacin, balanced salt solution (BSS), and an ocular lubricant (Systane) 4 times a day. Control eyes received only moxifloxacin, balanced salt solution, and ocular lubricant. Results No adverse events were observed with anti-IL-1. The safety of anti-IL-1 was affirmed because there was no statistically significant difference in time to epithelial closure, foam-layer histology and thickness, or final stromal thickness measurements between the anti-IL-1 and the steroid or control groups. No increase in haze was observed with anti-IL-1. There was a trend toward decreased haze with anti-IL-1 at several data points compared with the control and steroid groups. Finally, there was a trend toward less haze in all metrics at almost every timepoint for the 2.50 mg anti-IL-1 group compared with lesser concentrations. Conclusions Anti-IL-1 therapy might be a safe, effective alternative to steroids for haze prevention after PRK. Of the doses studied, 2.50 mg of anti-IL-1 4 times a day appeared to be most effective. Further studies in human eyes are needed. Financial Disclosure Dr. Reilly has been a consultant to Alcon Laboratories, Inc., and Abbott Medical Optics, Inc. None of the authors has a financial or proprietary interest in any material or method mentioned.

Original languageEnglish (US)
Pages (from-to)913-919
Number of pages7
JournalJournal of Cataract and Refractive Surgery
Volume42
Issue number6
DOIs
StatePublished - Jun 1 2016

Fingerprint

Photorefractive Keratectomy
Immunomodulation
Interleukin-1
Rabbits
Lubricants
Arm
Steroids
Fluorometholone
Salts
Refractive Surgical Procedures
Safety
Control Groups
Disclosure
Consultants
Interleukin-4
Suspensions
Histology
Research Design
Therapeutics
Joints

ASJC Scopus subject areas

  • Surgery
  • Ophthalmology
  • Sensory Systems

Cite this

Immunomodulatory therapy with anti-interleukin-1 after photorefractive keratectomy in the New Zealand white rabbit. / Taylor, Kenneth R.; Panday, Vasudha A.; Caldwell, Matthew C.; Petroll, W. Matthew; Apsey, Douglas A.; Reilly, Charles D.

In: Journal of Cataract and Refractive Surgery, Vol. 42, No. 6, 01.06.2016, p. 913-919.

Research output: Contribution to journalArticle

Taylor, Kenneth R. ; Panday, Vasudha A. ; Caldwell, Matthew C. ; Petroll, W. Matthew ; Apsey, Douglas A. ; Reilly, Charles D. / Immunomodulatory therapy with anti-interleukin-1 after photorefractive keratectomy in the New Zealand white rabbit. In: Journal of Cataract and Refractive Surgery. 2016 ; Vol. 42, No. 6. pp. 913-919.
@article{6e30504c3a0545eb938aaba87f37c70f,
title = "Immunomodulatory therapy with anti-interleukin-1 after photorefractive keratectomy in the New Zealand white rabbit",
abstract = "Purpose To examine the safety and efficacy of topical anti-interleukin-1 (anti-IL-1) following photorefractive keratectomy (PRK) in rabbit eyes. Setting Joint Warfighter Refractive Surgery Center, Lackland Air Force Base, Texas, USA. Design Experimental study. Methods After standard PRK, 48 eyes of 24 New Zealand white rabbits were divided into 4 treatment arms and 1 control arm. Eyes in the treatment arms were randomized to receive fluorometholone 0.1{\%} or an anti-IL-1 suspension (2.50 mg, 1.25 mg, or 0.25 mg doses) plus standard moxifloxacin, balanced salt solution (BSS), and an ocular lubricant (Systane) 4 times a day. Control eyes received only moxifloxacin, balanced salt solution, and ocular lubricant. Results No adverse events were observed with anti-IL-1. The safety of anti-IL-1 was affirmed because there was no statistically significant difference in time to epithelial closure, foam-layer histology and thickness, or final stromal thickness measurements between the anti-IL-1 and the steroid or control groups. No increase in haze was observed with anti-IL-1. There was a trend toward decreased haze with anti-IL-1 at several data points compared with the control and steroid groups. Finally, there was a trend toward less haze in all metrics at almost every timepoint for the 2.50 mg anti-IL-1 group compared with lesser concentrations. Conclusions Anti-IL-1 therapy might be a safe, effective alternative to steroids for haze prevention after PRK. Of the doses studied, 2.50 mg of anti-IL-1 4 times a day appeared to be most effective. Further studies in human eyes are needed. Financial Disclosure Dr. Reilly has been a consultant to Alcon Laboratories, Inc., and Abbott Medical Optics, Inc. None of the authors has a financial or proprietary interest in any material or method mentioned.",
author = "Taylor, {Kenneth R.} and Panday, {Vasudha A.} and Caldwell, {Matthew C.} and Petroll, {W. Matthew} and Apsey, {Douglas A.} and Reilly, {Charles D.}",
year = "2016",
month = "6",
day = "1",
doi = "10.1016/j.jcrs.2016.02.050",
language = "English (US)",
volume = "42",
pages = "913--919",
journal = "Journal of Cataract and Refractive Surgery",
issn = "0886-3350",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Immunomodulatory therapy with anti-interleukin-1 after photorefractive keratectomy in the New Zealand white rabbit

AU - Taylor, Kenneth R.

AU - Panday, Vasudha A.

AU - Caldwell, Matthew C.

AU - Petroll, W. Matthew

AU - Apsey, Douglas A.

AU - Reilly, Charles D.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Purpose To examine the safety and efficacy of topical anti-interleukin-1 (anti-IL-1) following photorefractive keratectomy (PRK) in rabbit eyes. Setting Joint Warfighter Refractive Surgery Center, Lackland Air Force Base, Texas, USA. Design Experimental study. Methods After standard PRK, 48 eyes of 24 New Zealand white rabbits were divided into 4 treatment arms and 1 control arm. Eyes in the treatment arms were randomized to receive fluorometholone 0.1% or an anti-IL-1 suspension (2.50 mg, 1.25 mg, or 0.25 mg doses) plus standard moxifloxacin, balanced salt solution (BSS), and an ocular lubricant (Systane) 4 times a day. Control eyes received only moxifloxacin, balanced salt solution, and ocular lubricant. Results No adverse events were observed with anti-IL-1. The safety of anti-IL-1 was affirmed because there was no statistically significant difference in time to epithelial closure, foam-layer histology and thickness, or final stromal thickness measurements between the anti-IL-1 and the steroid or control groups. No increase in haze was observed with anti-IL-1. There was a trend toward decreased haze with anti-IL-1 at several data points compared with the control and steroid groups. Finally, there was a trend toward less haze in all metrics at almost every timepoint for the 2.50 mg anti-IL-1 group compared with lesser concentrations. Conclusions Anti-IL-1 therapy might be a safe, effective alternative to steroids for haze prevention after PRK. Of the doses studied, 2.50 mg of anti-IL-1 4 times a day appeared to be most effective. Further studies in human eyes are needed. Financial Disclosure Dr. Reilly has been a consultant to Alcon Laboratories, Inc., and Abbott Medical Optics, Inc. None of the authors has a financial or proprietary interest in any material or method mentioned.

AB - Purpose To examine the safety and efficacy of topical anti-interleukin-1 (anti-IL-1) following photorefractive keratectomy (PRK) in rabbit eyes. Setting Joint Warfighter Refractive Surgery Center, Lackland Air Force Base, Texas, USA. Design Experimental study. Methods After standard PRK, 48 eyes of 24 New Zealand white rabbits were divided into 4 treatment arms and 1 control arm. Eyes in the treatment arms were randomized to receive fluorometholone 0.1% or an anti-IL-1 suspension (2.50 mg, 1.25 mg, or 0.25 mg doses) plus standard moxifloxacin, balanced salt solution (BSS), and an ocular lubricant (Systane) 4 times a day. Control eyes received only moxifloxacin, balanced salt solution, and ocular lubricant. Results No adverse events were observed with anti-IL-1. The safety of anti-IL-1 was affirmed because there was no statistically significant difference in time to epithelial closure, foam-layer histology and thickness, or final stromal thickness measurements between the anti-IL-1 and the steroid or control groups. No increase in haze was observed with anti-IL-1. There was a trend toward decreased haze with anti-IL-1 at several data points compared with the control and steroid groups. Finally, there was a trend toward less haze in all metrics at almost every timepoint for the 2.50 mg anti-IL-1 group compared with lesser concentrations. Conclusions Anti-IL-1 therapy might be a safe, effective alternative to steroids for haze prevention after PRK. Of the doses studied, 2.50 mg of anti-IL-1 4 times a day appeared to be most effective. Further studies in human eyes are needed. Financial Disclosure Dr. Reilly has been a consultant to Alcon Laboratories, Inc., and Abbott Medical Optics, Inc. None of the authors has a financial or proprietary interest in any material or method mentioned.

UR - http://www.scopus.com/inward/record.url?scp=85008694243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008694243&partnerID=8YFLogxK

U2 - 10.1016/j.jcrs.2016.02.050

DO - 10.1016/j.jcrs.2016.02.050

M3 - Article

C2 - 27373399

AN - SCOPUS:85008694243

VL - 42

SP - 913

EP - 919

JO - Journal of Cataract and Refractive Surgery

JF - Journal of Cataract and Refractive Surgery

SN - 0886-3350

IS - 6

ER -